The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The ten-day initiative, running from 10 to 21 November, brings together a team of highly skilled German doctors providing life-changing reconstructive surgeries at no cost
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
